Amylyx Pharmaceuticals (AMLX) Stock Analysis

What Amylyx Pharmaceuticals does

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Key metrics

ETFs linked to AMLX

Broad-market and Healthcare sector ETFs an investor holding Amylyx Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AMLX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals trades under the ticker AMLX on NASDAQ.

Which exchange is AMLX listed on?

AMLX is listed on NASDAQ.

What sector does Amylyx Pharmaceuticals operate in?

Amylyx Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AMLX in a portfolio?

PortView shows AMLX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.